SCHEMBL490486

SCHEMBL490486

CCOC(=O)C(Cc1ccc(OC)cc1)C(=O)OCC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.69
EPHX2 P34913 1/20 0.54
KMT2A Q03164 3/20 0.53
GLA P06280 1/20 0.53
MMP8 P22894 1/20 0.53
SLC6A4 P31645 1/20 0.49
ALDH1A1 P00352 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
MEN1 O00255 2/20 0.48
HTT P42858 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
CCR6 P51684 1/20 0.48
HKDC1 Q2TB90 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9247229 0.92 LDHA (0.59) LDHAEPHX2KMT2AGLAMMP8
Malonic Acid SCHEMBL6827835 0.92 LDHA (0.64) LDHAEPHX2KMT2AGLAMMP8
SCHEMBL854302 0.92 LDHA (0.63) LDHAEPHX2KMT2AGLAMMP8
SCHEMBL2570738 0.91 LDHA (0.61) LDHAEPHX2KMT2AGLAMMP8
SCHEMBL1312803 0.89 MMP8 (0.62) LDHAEPHX2KMT2AMMP8ALDH1A1
SCHEMBL3468330 0.87 LDHA (0.56) LDHAEPHX2KMT2AGLAMMP8
SCHEMBL18946161 0.86 MMP8 (0.59) LDHAEPHX2MMP8ALDH1A1PPARG
SCHEMBL5918555 0.86 LDHA (0.73) LDHASLC6A4HTTPPARGPPARA
SCHEMBL27429943 0.85 LDHA (0.59) LDHAEPHX2KMT2AMMP8ALDH1A1
SCHEMBL2241047 0.85 LDHA (0.57) LDHAEPHX2KMT2AGLASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238964-A2 Stabilised cosmetic compounds Henkel AG & Co. KGaA (DE) 2010-10-13 EP claimed
CN-112204065-B Process for preparing polyisocyanate polymers and polyisocyanurate plastics 科思创知识产权两合公司 2023-03-28 CN disclosed
CN-112204065-A Process for preparing polyisocyanate polymers and polyisocyanurate plastics 科思创知识产权两合公司 2021-01-08 CN disclosed
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
CN-101784520-B Novel malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORP 2014-07-02 CN disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
CN-1854128-B Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds MASSACHUSETTS INST TECHNOLOGY 2012-05-16 CN disclosed
US-8173664-B2 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2012-05-08 US disclosed
EP-1778236-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS Corcept Therapeutics, Inc. (US) 2007-05-02 EP disclosed
WO-2006111234-A1 UV PROTECTION MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed
WO-2006014394-A1 MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS CORCEPT THERAPEUTICS, INC. (US) 2006-02-09 WO disclosed
US-20060025405-A1 Modified pyrimidine glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (US) 2006-02-02 US disclosed
EP-0722321-A4 SULFOXIMINE AND SULFODIIMINE MATRIX METALLOPROTEINASE INHIBITORS UNIV FLORIDA STATE (US) 1998-04-15 EP disclosed
EP-0722321-A1 SULFOXIMINE AND SULFODIIMINE MATRIX METALLOPROTEINASE INHIBITORS FLORIDA STATE UNIVERSITY (US) 1996-07-24 EP disclosed
US-5470834-A Metalloproteinase enzyme inhibitors for arthritis, rheumatism and cancers FLORIDA STATE UNIVERSITY (US) 1995-11-28 US disclosed
WO-1995009620-A1 SULFOXIMINE AND SULFODIIMINE MATRIX METALLOPROTEINASE INHIBITORS FLORIDA STATE UNIVERSITY (US) 1995-04-13 WO disclosed
US-5204357-A RENIN-INHIBITING AMINO ACID DERIVATIVES HOECHST AKTIENGESELLSCHAFT (DE) 1993-04-20 US disclosed
EP-0329013-A2 Renin-inhibiting amino acid derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1989-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025405-A1 Modified pyrimidine glucocorticoid receptor modulators NR3C1, NR3C2, TYMS LDHA 3999/4885EPHX2 1883/4885KMT2A 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.